Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amyris, Inc. stock logo
AMRS
Amyris
$0.54
$0.05
$4.86
$18.47M1.1912.59 million shs46.75 million shs
Renalytix Plc stock logo
RNLX
Renalytix
$0.21
+5.7%
$0.23
$0.18
$2.40
$17.18M2.721.45 million shs934,400 shs
Cirata plc stock logo
WANSF
Cirata
$0.04
$0.34
$0.00
$1.90
$5.63M-19.921,229 shsN/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amyris, Inc. stock logo
AMRS
Amyris
0.00%0.00%0.00%0.00%0.00%
Renalytix Plc stock logo
RNLX
Renalytix
0.00%0.00%0.00%0.00%-81.83%
Cirata plc stock logo
WANSF
Cirata
0.00%0.00%-77.70%-10.80%-94.93%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amyris, Inc. stock logo
AMRS
Amyris
N/AN/AN/AN/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/AN/AN/AN/A
Cirata plc stock logo
WANSF
Cirata
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amyris, Inc. stock logo
AMRS
Amyris
0.00
N/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
3.00
Buy$3.001,348.58% Upside
Cirata plc stock logo
WANSF
Cirata
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amyris, Inc. stock logo
AMRS
Amyris
$269.85M0.00N/AN/A($1.52) per share0.00
Renalytix Plc stock logo
RNLX
Renalytix
$2.29M7.50N/AN/A($0.10) per share-2.07
Cirata plc stock logo
WANSF
Cirata
$6.70M0.84N/AN/A$0.25 per share0.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amyris, Inc. stock logo
AMRS
Amyris
-$528.51M-$1.93N/AN/AN/A-229.12%N/A-80.35%N/A
Renalytix Plc stock logo
RNLX
Renalytix
-$33.46M-$0.39N/AN/A-1,461.60%N/A-281.40%N/A
Cirata plc stock logo
WANSF
Cirata
-$36.48MN/A0.00N/AN/AN/AN/AN/A4/2/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amyris, Inc. stock logo
AMRS
Amyris
N/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/A
Cirata plc stock logo
WANSF
Cirata
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amyris, Inc. stock logo
AMRS
Amyris
N/A
0.52
0.29
Renalytix Plc stock logo
RNLX
Renalytix
N/A
0.53
0.53
Cirata plc stock logo
WANSF
Cirata
0.01
2.65
N/A

Institutional Ownership

CompanyInstitutional Ownership
Amyris, Inc. stock logo
AMRS
Amyris
62.76%
Renalytix Plc stock logo
RNLX
Renalytix
9.92%
Cirata plc stock logo
WANSF
Cirata
N/A

Insider Ownership

CompanyInsider Ownership
Amyris, Inc. stock logo
AMRS
Amyris
36.30%
Renalytix Plc stock logo
RNLX
Renalytix
18.30%
Cirata plc stock logo
WANSF
Cirata
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amyris, Inc. stock logo
AMRS
Amyris
1,598369.39 million235.30 millionOptionable
Renalytix Plc stock logo
RNLX
Renalytix
10082.96 million63.06 millionOptionable
Cirata plc stock logo
WANSF
Cirata
112126.31 millionN/ANot Optionable

Recent News About These Companies

Cirata Plc (CRTA.AQ)
Cirata plc (WANSF)
Cirata plc (CRTA.L)
WANdisco tries to come back from the brink

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amyris stock logo

Amyris NASDAQ:AMRS

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Renalytix stock logo

Renalytix NASDAQ:RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Cirata stock logo

Cirata OTCMKTS:WANSF

$0.04 0.00 (0.00%)
As of 03/11/2025

Cirata plc, together with its subsidiaries, engages in the development and provision of collaboration software in North America, Europe, China, and internationally. The company provides Data Migrator, an automated solution that moves on-premises HDFS data, Hive metadata, local filesystem, or cloud data sources to any cloud or on-premises environment; and Data Migrator for Hadoop, a cloud migration solution that automates the seamless transfer of HDFS data and Hive metadata to the cloud. It also offers Access Control Plus, an access control solution, that enables project administrators to manage the complexity of complete and proper authentication (AuthN) and authorization (AuthZ) configuration file generation; and Gerrit MultiSite, a development team collaboration solution, which enables replication of Gerrit server and packaged in a simple to deploy and maintain format. In addition, the company provides Git MultiSite and Subversion MultiSite Plus solutions enable distributed teams to collaborate as one with no downtime, no disruption, and consistent security policy enforcement across all locations. It offers its solutions for automotive, telecommunications, and financial service industries. The company was formerly known as WANdisco plc and changed its name to Cirata plc in October 2023. Cirata plc was incorporated in 2012 and is based in St. Helier, Jersey.